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Abstract
Background: Coronary heart disease (CHD) is a leading cause of morbidity and
mortality in African Americans. However, there is a paucity of studies assessing
genetic determinants of CHD in African Americans. We examined the association of
published variants in CHD loci with incident CHD, attempted to fine map these loci,
and characterize novel variants influencing CHD risk in African Americans.
Methods and Results: Up to 8,201 African Americans (including 546 first CHD
events) were genotyped using the MetaboChip array in the Atherosclerosis Risk in
Communities (ARIC) study and Women’s Health Initiative (WHI). We tested
associations using Cox proportional hazard models in sex- and study-stratified
analyses and combined results using meta-analysis. Among 44 validated CHD loci
available in the array, we replicated and fine-mapped the SORT1 locus, and
showed same direction of effects as reported in studies of individuals of European
ancestry for SNPs in 22 additional published loci. We also identified a SNP
achieving array wide significance (MYC: rs2070583, allele frequency 0.02,
P58.161028), but the association did not replicate in an additional 8,059 African
Americans (577 events) from the WHI, HealthABC and GeneSTAR studies, and in
a meta-analysis of 5 cohort studies of European ancestry (24,024 individuals
including 1,570 cases of MI and 2,406 cases of CHD) from the CHARGE
Consortium.
Conclusions: Our findings suggest that some CHD loci previously identified in
individuals of European ancestry may be relevant to incident CHD in African
Americans.
Introduction
The lifetime risk of coronary heart disease (CHD) at age 40 year in the U.S. is 1 in
2 for men and 1 in 3 for women [1], and higher in African Americans than whites
largely due to a higher burden of cardiovascular disease (CVD) risk factors in this
population [2]. CHD affects an estimated 16.3 million Americans, with a
prevalence of 7.9% in African American men and 7.6% in African American
women [2]. While in most industrialized countries CHD is the main cause of
death in adults, it also is a leading cause of heart failure, which also
disproportionally affects African Americans [3]. Genetic susceptibility to CHD has
been recently evaluated in genome wide association (GWA) studies, which reveal
approximately 44 loci for CHD in individuals of European ancestry [4–12] and in
East Asians [13–16]. Collectively, these variants represent a small fraction of the
genetic contribution to CHD risk [12].
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Despite the evidence for genetic susceptibility to CHD in African Americans
[17], there are few studies of CHD in African American individuals [18, 19]
perhaps due to limited availability of genotyped individuals and to the lower
representation of African ancestry-specific genetic variants by current GWA
arrays. Barbalic et al. studied the association of genotyped GWA (500K Affymetrix
6.0) single nucleotide polymorphism (SNPs) with incident CHD in 2,905 African
American participants of the Atherosclerosis Risk in Communities (ARIC) study,
and replicated a significant SNP association near the PFK1 gene in 8,000 African
American women from the Women’s Health Initiative (WHI) [18]. The study by
Lettre et al. tested the association of genotyped and HapMap imputed GWA SNPs
with prevalent CHD. It included 9,119 African Americans from the Candidate
Gene Association Resource (CARe) Project, of which 3,269 were ARIC
participants [19]. These prior studies included small sample sizes for discovery,
had low coverage of CHD GWA genomic regions [18, 19], or studied prevalent
CHD [19]. Published CHD loci have not been replicated in African Americans
[19]. In our prior study of the Population Architecture using Genomics and
Epidemiology (PAGE) study [20], we evaluated the association of the published
SNP with incident CHD events in three large cohort studies (ARIC, WHI and the
Cardiovascular Health Study [CHS]) by direct genotyping of SNPs [21]. We were
able to replicate prospective associations of CHD SNPs in individuals of European
ancestry [21] but not in the African American sample, which included 8,018
individuals and 808 CHD events. Differences in linkage disequilibrium (LD) and
tagging of functional SNPs in individuals of African ancestry, and differences in
allele frequencies or genetic and environmental background across populations
may explain much of these findings.
The NHGRI supported PAGE study genotyped African American individuals
on the MetaboChip, a high density custom Illumina iSelect array of
,200,000 SNPs that includes dense genotyping coverage for loci previously
associated with atherosclerotic, CVD and metabolic traits [22]. This array allows
examining the association of genotyped low frequency variants not previously
examined in GWA studies, in addition to have a more comprehensive coverage of
previously identified CHD loci compared to arrays used in prior studies. We
sought to examine the evidence for association of validated CHD loci identified in
case-control studies with incident CHD using a sample of up to 8,200 PAGE
African American individuals drawn from two large prospective cohort studies,
ARIC and WHI. Additionally, we sought to fine map these CHD susceptibility
loci, and characterize novel variants influencing CHD risk in African Americans.
Material and Methods
All participants included in these analyses have given consent for genetic studies
and data sharing. The University of North Carolina IRB and the Atherosclerosis
Risk in Communities and Women’s Health Initiative Publication and
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Presentation Committees have approved this study. Patient records/information
was anonymized and de-identified prior to analysis.
African American MetaboChip genotyped PAGE samples
The PAGE study includes eight well characterized population-based studies
assembled in four member studies of PAGE and its coordinating center. These are
Causal Variants Across the Life Course (CALiCo), which includes the ARIC,
Coronary Artery Risk Development in Young Adults (CARDIA), the
Cardiovascular Health Study (CHS), the Hispanic Community Health Study/
Study of Latinos (SOL), and Strong Heart Study (SHS); Epidemiological
Architecture for Genes Linked to Environment (EAGLE), accessing three National
Health and Nutrition Examination Surveys (NHANES); the Multiethnic Cohort
(MEC) Study; and WHI. All individual-level genotypes and phenotypes are
currently publicly available in dbGAP (ARIC is phs000280 - PAGE substudy
number is phs000223, and WHI is phs000200 (PAGE substudy number is
phs000227). We used data from African American participants of the CALiCo-
ARIC and the WHI studies.
The ARIC study is a multi-center cohort and community surveillance
investigation in predominantly bi-racial populations (white and African
Americans) [23]. ARIC recruited 15,792 individuals (of which 4,266 are African
Americans) aged 45–64 years from four communities in Forsyth County, N.C.,
Jackson, M.S., Minneapolis, M.N., and Washington County, M.D. for a baseline
examination in 1987–1989, with four follow-up examinations. Annual follow-up
and community surveillance identified CHD events (defined below) which are
then classified by an expert panel of physicians based on review of hospital
records, death certificates and interviews of next of kin [23]. All participants
included in these analyses have given consent for genetic studies and data sharing.
WHI is a prospective study investigating post-menopausal women’s health in the
U.S [24]. A total of 161, 838 women aged 50–79 years old were recruited from 40
US clinical centers between 1993 and 1998 to participate in an observational study
(OS) and in three clinical trials (CT). Annual (OS) and semi-annual (CT) follow-
up identified self-reported events which were then classified by an expert panel of
physicians based on review of hospital records, death certificates and interviews of
next of kin [25]. The CHD classification criteria are comparable between the WHI
and ARIC and were further harmonized for this study. A subset of 2,200 WHI
African American women was selected for the MetaboChip genotyping (sample 1)
and an additional 2,809 African American women genotyped in the PAGE
extension phase (sample 2) and included in the discovery phase. Women were
selected for genotyping on the basis of DNA and biomarker availability, and
consent. All participants included in these analyses have given consent for genetic
studies and data sharing. Additional study descriptions are shown in S1 File.
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Genotyping and quality control (QC) in PAGE
The MetaboChip array design includes SNPs associated at genome-wide
significance to any human trait published in the NHGRI GWA catalog as of
August 1, 2009 (including loci identified in the CARDIoGRAM for CHD), and an
additional proxy SNP with r2.0.90 in the CEU HapMap II dataset, plus up to
four additional SNPs with r2.0.5 in the YRI HapMap II dataset. SNPs were also
selected to fine-map regions of interest related to metabolic traits; copy number
variant-tagging SNPs, Major Histocompatibility Complex (MHC) SNPs, SNPs on
the X and Y chromosomes, mitochondrial DNA SNPs, and ‘‘wildcard’’ SNPs were
also targeted, for a total of approximately 200,000 SNPs. Several validated GWA
loci for CHD were fine mapped using 1000 Genome Project (1000 G) genotypes
and information from the GWA leading SNP or proxy obtained from large
consortia including the CARDIoGRAM, a consortium of case-control studies of
CHD [26]. In PAGE, study samples were genotyped separately in WHI and ARIC
studies following each genotyping center’s standard procedures. HapMap YRI
samples were also genotyped to facilitate cross-study QC. Standard QC was
applied for samples and SNPs including missing data and Hardy-Weinberg
Equilibrium (HWE). We also estimated identity-by-descent (IBD) statistics for all
pairs. Principal components were determined using the Eigensoft software
separately for each study [27]. We excluded ancestry outliers and first degree
relatives. Approximately 161,098 (81.9%) SNPs passed QC filters. The design and
performance of this genotyping chip in this African American sample has been
described in detail elsewhere [22].
CHD event definition and follow-up
ARIC and WHI have standardized protocols for the ascertainment and
classification of CHD events, defined as acute myocardial infarction (MI) and
fatal CHD. In ARIC, CHD events were ascertained from annual follow-up
interviews and morbidity and mortality surveillance of communities including
hospitalizations and deaths. Events were reviewed by two physicians and
differences adjudicated. CHD events were defined as acute hospitalized MI
(definitive or probable), definite fatal CHD, or ECG diagnosis of MI. Acute MI
was defined based on criteria that included cardiac pain, cardiac markers and ECG
readings. Events through December 31st, 2007 are included. In WHI, CHD was
defined as acute hospitalized MI (definitive or probable) and definite fatal CHD.
Acute MI was defined based criteria that included cardiac pain, cardiac markers
and ECG readings. Follow-up of events in WHI were through August 2009.
Replication samples for novel loci and secondary signals in
known loci
For novel loci identified in the array wide analyses, we attempted to validate the
findings using imputed data from additional studies of African ancestry including
WHI (n56,265), HealthABC (n5895) and GeneSTAR (n51,059), in addition to
Genetics of Incident Coronary Heart Disease
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24,024 individuals of European ancestry from the CHARGE Consortium. Because
our main findings showed little evidence for heterogeneity across sex-stratified
analysis, we allowed for combined sex results for replication. We attempted to
replicate secondary signals at known loci in these additional samples and in silico
using publicly available meta-analysis data from the CARDIoGRAM plusC4D
Consortium (http://www.cardiogramplusc4d.org/downloads/).
A subset of WHI African American women (n56,265) were genotyped as part
of the SNP Health Association Resource (SHARe) using Affymetrix 6.0 platform.
Description of the MetaboChip imputation in this subset is described elsewhere
[28]. This sample included 336 CHD incident events.
HealthABC is a prospective cohort study of 3,075 community-dwelling men
and women living in Memphis, Tennessee, USA and Pittsburgh, Pennsylvania,
USA, aged 70–79 years at recruitment in 1997 [29], of which 42% were African
Americans. A random sample of European ancestry and African American
Medicare-eligible elders, within designated zip code areas, were contacted.
Eligibility included reporting no difficulty with activities of daily living, walking a
quarter of a mile, or climbing ten steps without resting. All eligible participants
signed a written informed consent, approved by the IRBs at the clinical sites. This
study was approved by the IRBs of the clinical sites and the coordinating center
(University of California, San Francisco). Individuals with prevalent CHD defined
as MI, angina, bypass surgery, or percutaneous transluminal coronary angioplasty
(PTCA) procedures or diagnoses reported to the Centers for Medicare and
Medicaid Services in the five years prior to baseline, were excluded. Incident CHD
was defined as adjudicated event of MI, hospitalization for angina, or adjudicated
CHD death in participants who did not have prevalent CHD. The sample
included 895 participants and 223 events. Follow-up is through December 31,
2011, for a median of 11.0 years. Genotyping was done on Illumina 1 M
microarrays and the GWA data underwent standard QC procedures including
evaluation of genotype and self-reported sex concordance, sample call rate of 97%
or higher, exclusion of heterogeneity or homozygosity outliers, relatedness
(IBD.0.125 were excluded) and ancestry outliers. All SNPs were filtered for
inclusion based on a minimum call rate of 97%, HWE.1026, minor allele
frequency.1% and a missingness by haplotype p-value.1025. Samples were
imputed to the most recent multiethnic panel of the 1000 G reference haplotypes
(phase 1 alpha version 3) using MACH and minimac. Analyses were carried out
using R v2.14.2, with the first ten principal components in the African American
population as a means of controlling for population substructure.
The Genetic Study of Atherosclerosis Risk study (GeneSTAR) study identified
probands with documented premature (age,60 years) CHD events including MI,
coronary artery bypass surgery (CABG), percutaneous coronary intervention
(PCI), or $50% stenosis in one or more vessels confirmed on coronary
angiography with or without angina symptoms at the time of hospitalization in
one of 10 Baltimore, Maryland hospitals. Their apparently healthy siblings ,60
years of age and free of known CHD were recruited and screened from 1983 to
2007, and apparently healthy offspring of the probands or siblings were recruited
Genetics of Incident Coronary Heart Disease
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and screened from 2003–2007. Participants were excluded from the study for
systemic autoimmune disease, chest radiation exposure, any life-threatening
disease (AIDS or advanced cancer), or chronic glucocorticosteroid therapy.
Participants completed a standardized health status and cardiovascular disease
event questionnaire at approximately five-year intervals after their baseline visit
with trained telephone interviewers between 1992 and 2012. For deceased siblings,
proxy interviews were completed with the next of kin, and death certificates were
obtained. Medical records were then obtained for all reports of a CHD event, any
possibly related diagnosis, diagnostic procedure (including exercise tests, thallium
imaging, or coronary angiography) or therapeutic procedure (including PCI or
CABG). Incident CHD was defined as sudden cardiac death, definite or probably
MI, or coronary revascularization procedures (CABG or PCI). Genotyping was
performed with the Illumina Human 1Mv1_C chip at deCODE Genetics in
Reykjavik, Iceland; samples were excluded due to: 1) gender discrepancies, 2)
Mendelian inconsistency rate.5%, or 3) ancestry outliers from any of the first 10
principal components from EIGENSTRAT. SNPs missing chromosomal location,
SNPs with HWE p,1028, monomorphic SNPs, and SNPs with call rate ,90% or
with strand issues were excluded from analysis. Imputation to the 1000 G Phase I
Integrated Release Version 3 [March 2012] was performed with IMPUTE2. Data
were analyzed using R v2.15.1 (survival package), under an additive model.
The CHARGE Consortium performed a GWA analysis of incident MI and
CHD in 24,024 participants of European ancestry from five prospective cohort
studies (ARIC, CHS, Framingham Heart Study and Rotterdam study) including
1,570 cases of MI, and 2,406 cases of CHD. CHD was defined as fatal and non-
fatal MI and CVD mortality. Only first event was included.
Statistical analysis
Cox proportional hazard models were implemented in each discovery and
replication study, after excluding individuals with history of CHD at baseline. We
used additive genetic models (allele dosage) in sex-specific analyses and adjusted
for age at the first examination visit, center or geographic region and measures of
population stratification using study-specific principal components. Study-
specific log(hazard ratio) estimates were combined using inverse-weighted
variance meta-analyses methods [30]. We used a minor allele frequency of 0.01 for
filtering SNPs during meta-analysis. We also tested for the evidence of between-
study heterogeneity [31] using an alpha 50.05. Summary estimates (hazard ratio,
HR) and 95% confidence intervals (CI) are reported.
Fine mapping of known loci
We identified approximately 50 regions of interest based on previously reported
loci in European ancestry and Asians by querying the genome catalog for all
variants achieving a genome wide threshold of P,5.061028 for CHD
associations (http://www.genome.gov/gwastudies/). These included new CHD loci
published after the MetaboChip array was designed; of these only 44 loci had
Genetics of Incident Coronary Heart Disease
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SNPs genotyped on the MetaboChip array. We first evaluated the association of
previously published SNPs with incident CHD in the discovery sample of African
Americans. We then searched for the lowest p-value SNP in the region
(boundaries defined by 250 kb at each side of leading SNP or proxy) and
examined the LD of the SNP with the published SNP using LD statistics estimated
in the HapMap 1000 G CEU samples (representing European ancestry) and in the
ARIC/WHI African American data (representing African American LD). We
considered low LD as r2,0.3. We also examined if the direction of the effect for
the coded allele was the same between the original publication and the data
reported here. For the fine mapping analyses, we considered a Bonferroni
corrected p-value adjusted for the number of tested SNPs at each region (see
Table 1).
Analyses for novel loci
For the discovery of novel CHD loci in PAGE African Americans using the
MetaboChip, we applied a genome wide threshold of 2.861027 for 163,270 SNPs
tested based on a Bonferroni correction. SNPs with a P,1025 were carried
forward for replication in additional African American samples and in individuals
of European ancestry from the CHARGE Consortium. Replication was defined as
a Bonferroni corrected P,0.05 in the replication sample or a combined meta-
analysis discovery and replication P lower than the discovery P.
To functionally annotate validated CHD-associated SNPs we used HaploReg,
which integrates data from the ENCyclopedia Of DNA Elements (ENCODE)
Project Consortium [32–34] resources as well as other resources such as published
expression QTL studies. For CHD-associated SNPs that occur within annotated 39
untranslated regions (39 UTRs), we additionally examined the possibility of
microRNA target site creation/disruption by mining a recently published database
of genetic variants in candidate miRNA target sites [35].
Results and Discussion
The characteristics of the PAGE African American participants are shown in S1
Table. After QC, a total of 546 incident CHD events among the 8,201 African
American individuals with MetaboChip genotyping were available. The average
age at intake into the cohort was 54 years and 61 years in ARIC and the WHI
respectively, and their median follow-up was 18 years and 12 years.
Analyses of time to first CHD event were performed within each study and
within sex-strata. Study-specific genomic control values were ,1.0 after filtering
based on minor allele frequency of 0.01, indicating little evidence for global
population stratification (lambdas 0.93, 0.93 and 0.86 for ARIC women, ARIC
men, and WHI women, respectively). We first examined the evidence for
replication and fine mapping of previously published CHD loci for incident CHD
in African Americans (Table 1). The best evidence for SNP replication was at the
SORT1 locus, where rs583104 (minor allele frequency [MAF] 50.27,
Genetics of Incident Coronary Heart Disease
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P52.261024) is in complete LD with rs599839 (r251.0 in HapMap CEU,
P52.761023), the SNP described in the European ancestry GWAS [10, 13]
(Fig. 1). Each copy of the rs599839 A allele was associated with a 18% increased
hazard of CHD. All SNPs in 1000 Genomes Project (phase 3) HapMap CEU
samples with r2 with rs599839 greater than 0.25 lie within a 130 kb window
centered at rs599839 (displayed in Fig. 1). Of the 14 SNPs in the 1000 Genomes
Project (phase 3) with r2 in CEU samples greater than 0.5 with rs599839, 11 are on
the Metabochip. Only rs3902354 (r250.54 in CEU with rs599839), rs4970836
(r250.95), and rs4970837 (r250.56) are not on the Metabochip. Each of these 3
SNPs, however, is in high LD (r2.0.95) in CEU with SNPs on the Metabochip.
There was evidence for fine-mapping at this locus in African Americans, as only
3 SNPs (rs583104, rs602633 and rs1277930, encompassing a 0.8 Mbp region)
were correlated with rs599839 (r2.0.5) in African Americans compared to
11 SNPs (7.3 Mbp) in HapMap CEU 1000 G samples. The previously described
SNP rs12740374 (MAF 50.25) was not associated with incident CHD (P50.22)
and it was in low LD with rs599839 (r250.14) in our data. None of the remaining
published SNPs reached significance after adjusting for multiple testing, although
22 of 39 published SNPs available in our data, the estimates had the same
direction of effect as reported in studies of individuals of European ancestry
(Table 1).
Fig. 1. Regional plots of validated loci showing replication of the published SNP or proxy (a) or novel SNPs in known CHD loci (b, c). The X-axis
shows chromosomal positions and genes, the left Y-axis shows the –log10P-values and the right Y-axis shows the recombination rate across the region
using HapMap CEU linkage disequilibrium. Plotted SNP is the published SNP and is marked by a purple diamond and an arrow.
doi:10.1371/journal.pone.0113203.g001
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We then searched for additional SNPs associated with incident CHD in each
region and identified twenty-two loci that had at least one other SNP not in LD
with the published SNP (r2,0.3) with low p-value in the region (Table 1). These
SNPs included low frequency and common variants, and the associations did not
replicate in additional African American participants of WHI-SHARe and
GeneStar, or in European ancestry samples from the publicly available
CARDIoGRAM plusC4D meta-analysis (S2 Table).
We also evaluated the evidence for association of novel loci with incident CHD
in PAGE African American genotyped discovery samples. Meta-analyses of the
genotyped estimates from each study showed three SNPs, two within MYC and
one near to ADRA1A, associated with incident CHD and eligible for replication
based on a pre-specified threshold of P,1025 (Table 2). SNP rs2070583 (MAF
0.02), located at the 39UTR of the MYC gene, reached the Bonferroni-corrected
genome wide significant threshold for the MetaboChip array (P,2.861027). This
SNP was in strong LD with another SNP in the MYC gene (rs4645948) (r2.0.90,
HapMap YRI) (Fig. 2). These SNPs and an intergenic SNP near ADRA1A were
carried forward for replication in independent samples consisting of additional
8,059 African American individuals (577 CHD events) with 1000 G imputed data
(Table 2). The replication samples consisted of two samples of slightly older
individuals (mean age 73.3 years, standard deviation 2.9) than in PAGE samples
free of CHD at baseline (61.8 years, standard deviation 7.1) and an early CHD
sample (S1 Table). rs2070583 had a low imputation quality for a low frequency
variant in the available imputed samples from WHI and HealthABC data (rsq
50.73 and 0.53, respectively) and associations did not replicate for this SNP. The
other MYC SNP, rs4645948, and the SNP nearby the ADRA1A gene, rs1965328,
also did not replicate in the imputed African American samples. Allelic
frequencies ofMYC SNPs in European ancestry populations are similar to those in
the African American population. We therefore pursued replication in an
additional sample of European ancestry subjects with GWA data in the CHARGE
Consortium but found no evidence for replication of associations in these samples
(Table 1).
Finally, we identified several SNPs located in regions with some evidence of
regulatory function based on HaploReg analysis (S3 Table).
In this prospective genetic study of CHD in African American individuals using
a high density genotyping array, we replicated and fine-mapped one locus
(SORT1), which has not achieved significance in previous African American
studies for CHD or coronary artery calcification [19, 21, 36, 37]. In the SORT1
locus, the SNP with lowest p-value in the region (rs583104) was in LD with the
published SNP (rs599839). As previously reported, these SNPs occur within a
genomic region that is bound by numerous transcription factors, and is predicted
to alter the affinity of binding for some of those transcription factors (e.g., PU.1).
Of interest, the rs599839 risk allele showed same direction of effect but larger
magnitude of risk for incident CHD (hazard ratio 1.8) compared to published
cross-sectional case-control studies (odds ratio of 1.1 to 1.3) [6, 10]. Our study
Genetics of Incident Coronary Heart Disease
PLOS ONE | DOI:10.1371/journal.pone.0113203 December 26, 2014 12 / 18
T
a
b
le
2
.
A
ss
o
ci
a
tio
n
s
a
t
n
o
ve
l
lo
ci
fo
r
in
ci
d
e
n
t
C
H
D
in
A
fr
ic
a
n
A
m
e
ri
ca
n
s:
d
is
co
ve
ry
a
n
d
re
p
lic
a
tio
n
.
D
is
c
o
v
e
ry
R
e
p
li
c
a
ti
o
n
A
fr
ic
a
n
A
m
e
ri
c
a
n
s
*
A
fr
ic
a
n
A
m
e
ri
c
a
n
s
{
E
u
ro
p
e
a
n
a
n
c
e
s
tr
y
#
D
is
c
o
v
e
ry
a
n
d
re
p
li
c
a
ti
o
n
A
fr
ic
a
n
A
m
e
ri
c
a
n
s
N
e
a
rb
y
g
e
n
e
S
N
P
A
lle
le
M
A
F
E
ve
n
t/
To
ta
l
H
R
(9
5
%
C
I)
P
E
ve
n
t/
To
ta
l
P
E
ve
n
t/
To
ta
l
P
B
e
ta
(s
e
)
P
E
ve
n
t/
To
ta
l
M
Y
C
rs
2
0
7
0
5
8
3
A
/G
0
.0
2
5
4
6
/8
,2
0
1
2
.4
7
(1
.7
7
,
3
.4
4
)
8
.1
6
1
0
2
8
5
7
7
/8
,0
5
9
0
.3
0
2
,4
0
5
/2
4
,0
2
4
0
.7
9
2
0
.6
5
9
4
(0
.1
3
2
4
)
6
.3
6
1
0
2
7
1
7
,5
1
3
M
Y
C
rs
4
6
4
5
9
4
8
A
/G
0
.0
2
5
4
6
/8
,1
9
8
2
.4
6
(1
.7
4
,
3
.4
8
)
3
.8
6
1
0
2
7
5
7
7
/8
,0
5
9
0
.4
8
2
,4
0
5
/2
4
,0
2
4
0
.7
7
0
.6
2
5
9
(0
.1
4
0
4
)
8
.2
6
1
0
2
6
1
6
,2
5
7
A
D
R
A
1
A
rs
1
9
6
5
3
2
8
A
/G
0
.5
2
5
4
6
/8
,1
9
9
1
.3
2
(1
.1
7
,
1
.5
0
)
7
.9
6
1
0
2
6
5
7
7
/8
,0
5
9
0
.5
2
2
,4
0
5
/2
4
,0
2
4
0
.0
7
0
.1
1
6
6
(0
.0
4
3
7
)
7
.7
6
1
0
2
3
1
6
,2
5
8
C
I,
co
n
fid
e
n
ce
in
te
rv
a
l;
H
R
,
h
a
za
rd
ra
tio
;
M
A
F,
m
in
o
r
a
lle
le
fr
e
q
u
e
n
cy
;
N
,
n
u
m
b
e
r;
S
N
P
,
si
n
g
le
n
u
cl
e
o
tid
e
p
o
ly
m
o
rp
h
is
m
.
M
A
F
fo
r
S
N
P
s
in
H
a
p
M
a
p
C
E
U
sa
m
p
le
s
a
re
:
rs
2
0
7
0
5
8
3
G
a
lle
le
5
0
.0
0
9
,
rs
4
6
4
5
9
4
8
T
a
lle
le
5
0
.0
2
7
a
n
d
rs
1
9
6
5
3
2
8
A
a
lle
le
5
0
.2
6
5
.
P
fo
r
b
e
tw
e
e
n
-s
tu
d
y
h
e
te
ro
g
e
n
e
ity
w
a
s
n
o
t
si
g
n
ifi
ca
n
t.
S
N
P
s
w
e
re
e
lig
ib
le
fo
r
re
p
lic
a
tio
n
if
P
,
1
.0
6
1
0
2
5
.
T
h
e
a
rr
a
y
w
id
e
si
g
n
ifi
ca
n
t
th
re
sh
o
ld
is
P
,
2
.8
6
1
0
2
7
.
R
e
p
lic
a
tio
n
w
a
s
co
n
si
d
e
re
d
a
P
,
0
.0
5
in
re
p
lic
a
tio
n
sa
m
p
le
s
a
n
d
/o
r
a
P
le
ss
th
a
n
d
is
co
ve
ry
in
th
e
co
m
b
in
e
d
d
is
co
ve
ry
a
n
d
re
p
lic
a
tio
n
sa
m
p
le
s.
N
o
te
C
H
D
e
ve
n
ts
d
o
n
o
t
in
cl
u
d
e
p
ro
ce
d
u
re
s.
*
A
th
e
ro
sc
le
ro
si
s
R
is
k
in
C
o
m
m
u
n
iti
e
s
st
u
d
y
a
n
d
W
o
m
e
n
’s
H
e
a
lth
In
iti
a
tiv
e
st
u
d
y;
{
A
d
d
iti
o
n
a
l
sa
m
p
le
s
fr
o
m
W
o
m
e
n
’s
H
e
a
lth
In
iti
a
tiv
e
,
G
e
n
e
S
TA
R
a
n
d
H
e
a
lth
A
B
C
st
u
d
ie
s;
#
C
H
A
R
G
E
C
o
n
so
rt
iu
m
.
do
i:1
0.
13
71
/jo
ur
na
l.p
on
e.
01
13
20
3.
t0
02
Genetics of Incident Coronary Heart Disease
PLOS ONE | DOI:10.1371/journal.pone.0113203 December 26, 2014 13 / 18
shows consistency in the direction of effect for additional 22 published SNPs,
although associations did not reach the significance threshold.
Our novel finding at the MYC gene is for two low frequency variants (MAF
50.02) including rs2070583, a SNP located on the 39 UTR gene region, which
showed 2.5-fold higher’ hazard of CHD per copy of the A allele, although the
associations remained suggestive given the lack of replication of findings. c-myc
protein is a transcription factor with function in cell cycle progression, apoptosis
and cellular transformation [38], recently shown to relate to coronary vascular
development and remodeling [39]. There is additional biological support for the
relevance of this gene to CVD. For example, c-myc +/- heterozygote mice display
decreased coronary vasculature when compared to wild type (WT) littermates
[39] and mice with induced c-myc expression in cardiomyocytes develop
hypertrophic cardiomyopathy, ventricular dysfunction and heart failure [40].
However, we were unable to validate this locus in our replicating samples. This
association is unlikely to be identified previously due to the low frequency of these
variants (MAF 50.02) and low coverage of this gene in other genome arrays. This
may explain at least in part our failure to replicate the results in African
Americans and individual of European ancestry in which the coverage of theMYC
−
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Fig. 2. Regional plots of the MYC loci showing two SNPs and their LD. The X-axis shows chromosomal positions and genes, the left Y-axis shows the –
log10P-values and the right Y-axis shows the recombination rate across the region using HapMap CEU linkage disequilibrium. Plotted SNPs are marked by
arrows.
doi:10.1371/journal.pone.0113203.g002
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gene is poor. In addition, as compared to genotyped data used for the discovery,
the replication samples consisted of imputed data with varying quality of
imputation. Therefore, we cannot exclude false positive results for this locus,
which should be further investigated in studies using exome data.
This is the largest genetic study to use adjudicated incident clinical events in
African Americans. In contrast to most prior genetic studies of CHD, our analysis
was restricted to harmonized, adjudicated incident clinical events among
individuals without prior history of CHD. This study differs from prior studies by
using prospective incident data instead of a case-control design. In addition, we
used a high density genotyping array which included common and low frequency
genotyped variants from 44 published CHD loci. However, our study is limited by
the available samples and the coverage of the genotyped array. We have reasonable
power to detect HRs of 1.4 and greater for SNPs with allele frequencies greater
than 0.25 and HRs of 1.6 for SNP with allele frequency between 0.05 and 0.25 (S2
File). There is some overlap of individuals in the ARIC study from the previously
reported incident CHD paper by Barbalic et al, which examined 2,905 participants
as compared to 3,204 used in our analysis. This prior publication studied only
GWA genotyped data, with low coverage on several loci described in our study.
In summary, in loci previously reported to be associated with CHD, a published
SNP (rs599839, SORT1) was associated with incident CHD in African American
individuals. We also provide evidence for fine-mapping at this locus, and
identified an array wide association for a SNP in MYC, a gene with some biology
plausibility for CHD traits, which will require further validation in additional
samples. This study extends the genetic findings of associations of validated CHD
to African Americans and for incident CHD events.
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